BeneluxBio BV is a company that develops new drugs for neurological disorders, including cancer and infectious diseases of the brain. We have developed an innovative small-molecule platform technology specifically designed to overcome the biological blood-brain barrier and target the underlying disease mechanisms in the central nervous system (CNS). BeneluxBio consists of a team of four people, each with their own complementary expertise, and a number of advisors. In addition, BeneluxBio is part of a network that emerged following the acquisition of 
Organon. On September 1, 2026, the Shuttle To Brain project was launched, comprising 3 universities, 2 academic hospitals, and 4 SMEs from Belgium, the Netherlands, and Germany. BeneluxBio is one of the 9 partners .